Gidi Benyamini has joined Notal Vision as COO. Gidi had spent 7 years at Scitex in Israel. Located in Tel Aviv Israel, Notal Vision Ltd. develops Macular Computerized Psychophysical Test, which provides early detection, referral and treatment of Age-related Macular Degeneration. These are critical to prevent vision loss and to maximize treatment benefits.
AMD is the leading cause of blindness in the developed world among people over the age of 50. About 14 million people in the US suffer from AMD and it is the cause of blindness among 1.7 million Americans.
Notal Vision’s MCPT is currently being clinically verified by prominent ophthalmology clinics. Availability of the product is expected in early 2002, after FDA approval.